rs822391 — ADIPOQ IVS1+407C>T

ADIPOQ rs822391 — An Intronic Switch That Dims Your Adiponectin Signal

Adiponectin is one of the body's most protective metabolic hormones — secreted exclusively by fat cells, it simultaneously suppresses hepatic glucose output, activates AMPK in skeletal muscle, and shields artery walls from inflammation. People with high circulating adiponectin have meaningfully lower rates of type 2 diabetes, coronary artery disease, and ischemic stroke. rs822391 is an intronic C-to-T substitution in the first intron of ADIPOQ¹¹ ADIPOQ
The gene encoding adiponectin (also called APM1 or Acrp30), located at chromosome 3q27 — a locus strongly and repeatedly confirmed as the primary genetic determinant of circulating adiponectin levels in population studies, sitting 407 nucleotides into intron 1 at GRCh38 position chr3:186,846,014. The C allele (the minor allele, at roughly 20% frequency in Europeans and only 4% in Africans) has been associated with ischemic stroke risk and is implicated in modulation of adiponectin output at the 3q27 locus.

The Mechanism

Intronic variants in ADIPOQ influence adiponectin levels through several possible mechanisms: disruption of intronic enhancer elements²² intronic enhancer elements
Regulatory sequences within introns that recruit transcription factors to boost gene expression from a distance; intron 1 of ADIPOQ contains multiple such elements active in adipocytes, alterations in pre-mRNA splicing³³ pre-mRNA splicing
The process removing introns from precursor RNA; variants within the first few hundred nucleotides of an intron can affect splice site recognition and exon inclusion rates even without changing the consensus AG/GT dinucleotides, or tagging of nearby functional variants through linkage disequilibrium⁴⁴ linkage disequilibrium
The tendency for nearby genetic variants to be inherited together as a haplotype; rs822391 sits in the same ADIPOQ locus LD block as known functional variants including rs2241766 (T45G) and rs1501299 (+276G>T). The rs822391 C allele is the minor allele globally, with strong population stratification: frequency of roughly 20% in Europeans and South Asians, 10% in East Asians, and as low as 4% in African populations — a pattern consistent with population-specific selection acting on the ADIPOQ locus. The GTEx database identifies this variant as an eQTL for ADIPOQ-AS1 in testis tissue (NES −0.23, p=1.6×10⁻⁹), and the T allele shows positive regulatory effects in arterial tissue (NES +0.21, p=4.2×10⁻⁵), suggesting allele-specific effects on ADIPOQ-neighborhood gene regulation.

The Evidence

The most direct clinical evidence for rs822391 comes from a Korean case-control study by Cheong et al. (2011)⁵⁵ Cheong et al. (2011)
Six ADIPOQ polymorphisms were genotyped in a stroke vs. control cohort; rs822391 was among those showing significant association in both dominant and additive logistic regression models after adjustment for age and sex, which reported that the C allele (described in that paper as the T>C substitution, confirming C as the risk direction on the plus strand) was significantly associated with ischemic stroke risk (p<0.05). This is biologically coherent: adiponectin is an established anti-atherosclerotic and anti-thrombotic hormone, and variants that reduce its circulating levels — including rs822391 C allele carriers — face downstream consequences in cerebrovascular protection.

At the broader locus level, Heid et al. (2010)⁶⁶ Heid et al. (2010)
Genome-wide association analyses of 4,659 Europeans followed by replication in 13,795 additional subjects, n=18,454 total, identifying ADIPOQ as the dominant genetic determinant of plasma adiponectin established that the ADIPOQ 3q27 region explains approximately 6.7% of variance in circulating adiponectin levels in Europeans — the single largest genetic contributor to this phenotype. rs822391 lies within this locus, and the Jackson Heart Study (n>5,000 African Americans) included it among a panel of ADIPOQ variants examined for adiponectin associations with gender-specific effects, finding locus-wide signals concentrated in several correlated variants including rs16861205, a close neighbor at chr3:186,843,845.

On the intervention side, Sepidarkish et al. (2022)⁷⁷ Sepidarkish et al. (2022)
Systematic review and meta-analysis of 43 randomized controlled trials, n=3,434 participants across diverse populations demonstrated that omega-3 fatty acid supplementation raises circulating adiponectin with a pooled effect size of SMD 0.21 (95% CI 0.04–0.37, p=0.01), with the strongest effects at doses exceeding 2,000 mg EPA/DHA per day for more than 10 weeks. This intervention-level evidence directly informs the management of C allele carriers whose baseline adiponectin is already genetically suppressed.

Practical Actions

Carriers of the C allele cannot override the intronic regulatory change, but circulating adiponectin is modifiable through targeted nutrition. Long-chain omega-3 fatty acids (EPA and DHA) are the best-supported dietary upregulators of adiponectin, acting through PPAR-alpha activation in adipocytes to increase ADIPOQ transcription — a mechanism that partially compensates for genetically lower baseline secretion. Saturated fatty acids specifically suppress ADIPOQ promoter activity through competitive PPAR-gamma antagonism, so replacing saturated fat with mono- and polyunsaturated sources measurably raises adiponectin independent of total caloric intake.

Given the documented association with stroke risk, C allele carriers — particularly CT and CC individuals — benefit from monitoring the biomarkers that reflect the downstream consequences of lower adiponectin: fasting serum adiponectin, fasting insulin, and blood pressure. Early detection of hypoadiponectinemia (below 5 µg/mL) or elevated fasting insulin (above 8 µIU/mL) allows targeted intervention before vascular consequences develop.

Interactions

rs822391 lies within the same ADIPOQ intron 1 locus block as rs16861194 (−11426A>G upstream promoter), rs16861205 (intron 1 A>G), and nearby rs1501299 (+276G>T, intron 2). Individuals carrying risk alleles at multiple ADIPOQ locus variants — which tend to cluster in the same low-adiponectin haplotype — show substantially greater reductions in circulating adiponectin than any single variant predicts. The compounding of rs822391 C allele with rs2241767 G or rs1501299 T creates a high-priority metabolic target where direct adiponectin measurement is especially warranted. See related SNPs for individual variant profiles.